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CASE PRESENTATION
A 31-year-old human immunodeficiency virus (HIV)-
positive Hispanic male presented with gross hematuria
and renal insufficiency. The patient had an episode of
gross hematuria 3 months before that lasted 1 week and
subsided spontaneously. Urologic workup including
abdominal and pelvic computed tomography (CT) scan,
cystoscopy, and renal ultrasound was negative. Gross
hematuria recurred a few weeks later. During this 3-month
time period, the patient’s serum creatinine increased from
1.6 mg/dl (141mmol/l) to 2.7 mg/dl (239mmol/l). Past
medical history was significant for HIV infection for
7 years, acquired via homosexual contact, and bipolar
disorder. At the time of presentation, the patient was on
multiple antiretroviral medications including indinavir
(800 mg twice a day), ritonavir (100 mg twice a day), and
lamivudine (150 mg a day), all of which had been initiated
26 months before. The patient was also being treated for
bipolar disorder with olanzapine (10 mg a day) and
lamotrigine (100 mg a day). Other medications included
AndroGels (testosterone replacement gel) (once a day)
and dronabinol (2.5 mg a day).
On physical examination, the patient had a blood
pressure of 120/80 mm Hg, a heart rate of 62/min, and a
weight of 155 pounds. He was afebrile. Cardiovascular,
pulmonary, and abdominal examinations were
unremarkable. He had a rash on his hands and lower
abdomen. The rash was pruritic with excoriations,
presumably allergic, and subsequently resolved. There
was no evidence of edema. Laboratory examination
showed a total leukocyte count of 8000/mm3 (normal
range 3800–10 800/mm3) with an absolute lymphocyte
count of 2688/mm3 (normal range 850–3900/mm3),
eosinophil count 128/mm3 (normal range 15–550/mm3),
hematocrit 39% (normal range 38.5–50.0%), platelet count
634 109/l (normal range 140–400 109/l), 24 h urine
protein 1.3 g, serum albumin 4.5 g/dl (45 g/l) (normal
range 3.7–5.1 g/dl (37–51 g/l)), and creatinine clearance
27 cm3/min. The following serologies were negative:
antinuclear antibody, anti-double-stranded DNA antibody,
anti-neutrophil cytoplasmic antibody, anti-GBM antibody,
hepatitis B surface antigen, and hepatitis C antibody. His
viral load was o50 HIV-1 RNA copies/ml (reference range
o50 copies/ml). The CD4 count was 515/mm3 (reference
range 490–1740/mm3). Urinalysis showed trace protein,
moderate blood, pH 6.0, negative nitrite, and positive
leukocytes. Microscopic evaluation of the urine sediment
(performed once) revealed 10 red blood cells/high power
field, no casts, and no crystals. The clinical differential
diagnosis included HIV-associated nephropathy (HIVAN),
immune complex glomerulonephritis, and highly active
antiretroviral therapy (HAART)-associated nephrotoxicity.
A renal biopsy was performed.
RENAL BIOPSY FINDINGS
Light microscopic examination disclosed one core of renal
cortex and one core of cortex and medulla. There were 25
glomeruli, none of which were segmentally or globally
sclerotic. Glomeruli appeared histologically unremarkable,
without evidence of collapsing sclerosis or podocyte hyper-
plasia. Approximately 30% of the cortex and medulla
displayed patchy tubular atrophy, interstitial fibrosis, and
chronic inflammation by lymphocytes, monocytes, and
plasma cells, without eosinophils or granulomas. In these
areas, there was rare mild tubulitis and multifocal interstitial
microhemorrhage. The tubules contained multiple casts
composed of stacks of clear crystals with needle-shaped or
rod-shaped appearance surrounded by intratubular mono-
nuclear and giant cells (Figure 1a and b). The crystals failed
to stain with the hematoxylin and eosin, periodic acid-Schiff,
and trichrome stains, and did not polarize. The involvement
by crystalline casts was patchy with predominant involve-
ment of the medullary collecting tubules and cortical distal
and collecting tubules, with sparing of adjacent broad zones
of cortex. There were associated focal tubular degenerative
and regenerative changes. No mycobacteria or fungi were
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detected by acid fast bacillus (AFB) and Gomori methena-
mine silver (GMS) stains. Vessels displayed mild arterio-
sclerosis and arteriolar hyalinosis.
The seven glomeruli sampled for immunofluorescence
were negative for IgG, IgM, IgA, C1, and kappa and lambda
light chains. There was weak nonspecific granular mesangial
positivity for C3. On ultrastructural evaluation, glomeruli
showed no evidence of immune-type electron dense deposits,
endothelial tubuloreticular inclusions, or foot process efface-
ment. The intratubular crystals were composed of relatively
electron lucent material accompanied by intraluminal mono-
nuclear reaction and acute tubular injury.
FINAL DIAGNOSIS
Acute and chronic interstitial nephritis with crystalline casts,
consistent with indinavir nephrotoxicity.
CLINICAL FOLLOW-UP
Following the biopsy, indinavir was discontinued and all
other medications were maintained. Two months later, the
serum creatinine declined to 1.7 mg/dl (150 mmol/l). There
was no recurrence of gross hematuria. The patient’s HIV
infection remained well controlled with a viral load of o50
HIV-1 RNA copies/ml, CD3þ /CD4þ cells 30% (reference
range 30–61%), CD3þ /CD4þ count of 515/mm3, and an
absolute lymphocyte count of 1691/mm3.
DISCUSSION
The introduction of combination HAART for the treatment
of HIV infection over the last decade has resulted in a
dramatic reduction in the morbidity and mortality resulting
from AIDS and HIV-related disease. HAART typically
includes the combination of two reverse transcriptase
inhibitors (RTIs) plus a protease inhibitor (PI) or three
RTIs. A variety of adverse effects of HAART therapy
have been recognized, including lipodystrophy syndrome,
hyperlipidemia, lactic acidosis, osteopenia and osteoporosis,
and hyperglycemia. Importantly, renal toxicity has been
associated with several of these antiretroviral agents1–12
(Table 1).
Among the RTIs currently approved to treat HIV
infection, tenofovir has been associated with toxic acute
tubular necrosis and proximal tubular dysfunction resulting
in incomplete Fanconi syndrome.9 Similar, but much
more frequent, nephrotoxicity has been reported with the
other two nucleotide RTIs: cidofovir (at a dose of 5 mg/week)
used to treat cytomegalovirus infection and adefovir (at a
dose of 30 mg/day or higher), which is not currently
FDA approved for treatment of HIV infection because
of its serious side effects.8 Mitochondrial DNA depletion
owing to inhibition of DNA polymerase g, the major
enzyme responsible for replication of mitochondrial DNA,
has been proposed as a major mechanism of systemic
and renal toxicity of RTIs.8 Of note, the low-dose
regimens of cidofovir (0.25 mg/kg a week) and adefovir
(5–10 mg/day) used currently to treat BK polyoma interstitial
nephritis and lamivudine-resistant chronic hepatitis B
infection, respectively, are not generally associated with
nephrotoxicity.
Among protease inhibitors, indinavir is the one most
frequently associated with adverse renal and urologic effects.
Indinavir (Crixivans), first introduced in 1996, is one of the
most widely prescribed protease inhibitors for the treatment
of HIV infection. It blocks activity of the HIV-encoded
protease required for cleavage of the gag and pol precursor
polypeptides, resulting in the formation of immature,
noninfectious viral particles. Eighty-one percent of the
administered dose is metabolized in the liver and excreted
through the bile. The remaining 19% is eliminated by the
kidneys, of which 11% is excreted as an unchanged
compound and 8% as a variety of metabolites.13 Indinavir
solubility is high in acidic urine (100 mg/ml at pH 3.5)
but very low at physiologic urine pH (0.03 mg/ml at pH 6),
a
b
Figure 1 | Renal biopsy findings. (a) A low-power view shows three
tubules of probable distal or collecting tubular origin (arrows)
containing abundant clear intraluminal crystals with needle and rod
shapes surrounded by mononuclear cells and giant cells. The
adjacent interstitium contains a dense infiltrate of mononuclear
leukocytes (hematoxylin & eosin, original magnification 200).
(b) A high-power view illustrates the clear intratubular crystals
(arrows) engulfed by intraluminal giant cells (arrowheads)
(hematoxylin & eosin, original magnification 400).
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resulting in intratubular precipitation and intrarenal
obstruction.
The spectrum of urologic/nephrologic abnormalities
associated with indinavir therapy includes dysuria, flank
pain, renal colic, hematuria, crystalluria, nephrolithiasis,
acute renal failure, chronic renal failure, and papillary
necrosis. In a study of 1219 HIV patients on protease
inhibitor treatment by Dieleman et al.,1 the incidence of
urologic/nephrologic symptoms was 8.3/100 treatment-years
for indinavir vs. 0.8/100 treatment-years for other HIV
protease inhibitors. Risk factors for the development of these
symptoms included low lean body mass, warm environ-
mental temperatures, indinavir regimens of 1000 mg or
higher twice daily, and minimal HIV-1 RNA at the start
of indinavir therapy. Most of the symptoms occurred within
6 months of initiating indinavir therapy.
Asymptomatic crystalluria is observed in approximately
one-fifth of patients on indinavir.2 Viewed under a micro-
scope equipped with a polarizer and a lambda plate, the urine
crystals appear birefringent and display varied shapes,
including rectangles, starbursts, and fans.2 Symptomatic
nephrolithiasis occurs in 3–12% of patients.2,14 The stones
are most commonly composed of pure indinavir sulfate,
which is radiolucent on plane abdominal X-ray and CT
scan.15 Intravenous urogram, renal ultrasonography, and
nuclear medicine renography are helpful diagnostic tests.
Occasionally, radio-opaque mixed stones composed of
indinavir and calcium salts may form. The majority of
patients can be managed conservatively with hydration and
spasmo-analgesic drugs. Urinary acidification to increase
indinavir solubility is difficult to achieve and not recom-
mended because it increases the risk of uric acid urolithiasis.
Discontinuation of indinavir therapy is rarely needed to
manage nephrolithiasis that is not complicated by renal
dysfunction.
The development of renal failure that is typically preceded
by persistent sterile pyuria has been reported to occur in
18–33% of patients on indinavir16–18 and is usually mild and
reversible. Renal biopsy findings of indinavir toxicity have
been reported in only 13 patients, including 12 adults and
one child17,19–26 (Table 2). These 13 patients generally
presented with a slow asymptomatic rise in serum creatinine.
The daily indinavir dose was 2400 mg (800 mg three times a
day) in 12 patients and 1500 mg (500 mg three times a day) in
one patient. The mean peak serum creatinine was 1.9 mg/dl
(range 1.1–3.0 mg/dl). The mean duration of indinavir
treatment at the time renal failure was first detected was
approximately 6 months (range 1–9 months) in the 11 cases
with available data. Pyuria, eosinophiluria, and urine crystals
were reported in 12 patients (92%), five patients (38%), and
five patients (38%), respectively. Histologically, there was
interstitial inflammation, frequently accompanied by tubular
atrophy and interstitial fibrosis. In 11 cases (85%), clear,
needle-shaped indinavir crystals were identified in the lumina
of tubules, particularly involving collecting ducts. The
crystals were commonly associated with mononuclear and
giant cell reaction. Indinavir was discontinued in all 12 cases
with available follow-up data, leading to improvement in
renal function in all cases. After a mean follow-up of 8 weeks
following indinavir withdrawal, the mean serum creatinine
had fallen from 1.9 to 1.2 mg/dl. Importantly, since the
establishment of the currently recommended indinavir
dosage of 400 mg twice a day. (half the formally prescribed
dose), no new cases of indinavir nephrotoxicity have never
been reported.
We describe an additional biopsy-proven case of indinavir-
induced crystal nephropathy. The patient, who was treated
with 800 mg twice a day of indinavir, presented with
recurrent gross hematuria and renal insufficiency. The gross
hematuria could have been secondary to papillary necrosis,
radiolucent indinavir calculi not detected by computed
tomography scan or cystoscopy, or the multiple foci of
medullary interstitial microhemorrhage noted surrounding
the intraparenchymal crystals. In our patient, prompt
Table 1 | List of HAART drugs associated with nephrotoxicity
HAART subfamily Name Renal side effects References
Protease inhibitors Indinavir Crystalluria, nephrolithiasis, dysuria, acute interstitial nephritis
with crystalline casts in tubules, and papillary necrosis
1–3
Ritonavir Acute renal failure 4–5
Atazanavira Acute interstitial nephritis 6




Adefovir Acute tubular toxicity, and partial Fanconi syndrome 8














HAART, highly active antiretroviral therapy.
aVery rare association limited to single case reports.
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discontinuation of indinavir therapy without steroid treat-
ment resulted in a nearly complete recovery of renal function.
The renal biopsy was useful to establish a diagnosis of
indinavir-induced crystal nephropathy and exclude other
potential causes of renal failure such as allergic interstitial
nephritis, acute tubular necrosis, HIV-associated nephro-
pathy, immune-complex glomerulonephritis, direct renal
parenchymal infection by opportunistic organisms, and acute
renal failure associated with immune restoration inflamma-
tory syndrome. Immune restoration inflammatory syndrome
is a systemic inflammatory response to previously treated,
inactive opportunistic infections that occurs in AIDS patients
after initiation of HAART therapy, leading to enhanced
immune responses. Immune restoration inflammatory syn-
drome-associated renal involvement is rare and is character-
ized clinically by acute renal failure and histologically by
granulomatous acute interstitial nephritis that usually
responds to steroid therapy.27
The differential diagnosis of crystalline nephropathy in the
HIV-infected patient also includes foscarnet toxicity. Foscar-
net is an antiviral agent typically used to treat cytomegalo-
virus retinitis. Foscarnet crystals differ histologically from
indinavir crystals in three ways: they predominantly involve
glomerular capillaries, they appear yellowish on hematoxylin
and eosin, and they are usually admixed with sodium calcium
salts, which causes them to stain black with the Von Kossa’s
reaction.28
In summary, indinavir-induced crystal nephropathy must be
considered in the differential diagnosis of renal failure occurring
in HIV patients on HAART therapy. Examination of urine
sediment for indinavir crystals, intravenous urogram and renal
ultrasonography to detect the radiolucent indinavir stones, and
renal biopsy are helpful diagnostic procedures. Indinavir
withdrawal generally results in recovery of renal function.
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